GSN transcriptional repression is associated with epigenetic control through DNA methylation and histone deacetylation, and addition of HDAC inhibitors increases GSN expression [51], which supports its use as a biomarker for the effectiveness of MPNST treatment with HDAC inhibitors. Here, GSN is linked to malignant peripheral nerve sheath tumor.